Safety Evaluation of Modern Oral Contraceptives
| Autor: | I F Godsland, David Crook |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
medicine.medical_specialty
Progestogen business.industry Cholesterol Insulin medicine.medical_treatment Obstetrics and Gynecology Physiology Disease Carbohydrate metabolism chemistry.chemical_compound Endocrinology High-density lipoprotein Reproductive Medicine chemistry Desogestrel Oral administration Internal medicine medicine business medicine.drug |
| Zdroj: | Contraception. 57:189-201 |
| ISSN: | 0010-7824 |
| DOI: | 10.1016/s0010-7824(98)00018-3 |
| Popis: | An ideal oral contraceptive should either be neutral as regards metabolic risk markers for arterial disease or should only change them in directions that would be expected to reduce risk. Depending on their formulation, modern low dose oral contraceptives affect systems such as hemostasis, lipoprotein metabolism, and glucose and insulin metabolism. Some of these actions would be expected to decrease the risk of arterial disease and some might be expected to increase risk. Despite these associations there is at present no justification for widespread metabolic screening as a strategy to further improve oral contraceptive safety. Recent developments in atherosclerosis research support the introduction of progestogens such as desogestrel that allow the estrogenic increase in high density lipoprotein levels to persist and that may cause less of an elevation in plasma insulin responses to glucose. The predicted benefit of these formulations in terms of arterial disease is difficult to demonstrate in an epidemiological setting because of the rarity of the disease in young women. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect